EX-23.1 5 ocgn-20241231x10kxex231.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statement (Form S-3 No. 333-234127) of Ocugen, Inc.,

(2)Registration Statement (Form S-8 No. 333-237454) pertaining to the Ocugen, Inc. 2019 Equity Incentive Plan and the Ocugen, Inc. 2014 Stock Option Plan,

(3)Registration Statement (Form S-8 No. 333-254549) pertaining to the Ocugen, Inc. 2019 Equity Incentive Plan,

(4)Registration Statement (Form S-8 No. 333-263063) pertaining to the Ocugen, Inc. Inducement Stock Option and Restricted Stock Unit Awards (June 2021 – February 2022),

(5)Registration Statement (Form S-8 No. 333-263064) pertaining to the Ocugen, Inc. 2019 Equity Incentive Plan,

(6)Registration Statement (Form S-8 No. 333-270082) pertaining to the Ocugen, Inc. Inducement Stock Option and Restricted Stock Unit Awards (March 2022 – September 2022),

(7)Registration Statement (Form S-8 No. 333-270083) pertaining to the Ocugen, Inc. 2019 Equity Incentive Plan,

(8)Registration Statement (Form S-8 No. 333-278773) pertaining to the Ocugen, Inc. 2019 Equity Incentive Plan,

(9)Registration Statement (Form S-3 No. 333-278774) of Ocugen, Inc., and

(10)Registration Statement (Form S-3 No. 333-284629) of Ocugen, Inc.;

of our report dated April 16, 2024, with respect to the consolidated financial statements of Ocugen, Inc. included in this Annual Report (Form 10-K) of Ocugen, Inc. for the year ended December 31, 2024.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

March 5, 2025